Publications by authors named "Juan A Pineyroa"
The presence of a monoclonal protein detected by serum immunofixation electrophoresis (sIFE) has been reported as an adverse prognostic factor in chronic lymphocytic leukemia (CLL). However, the genetic underpinning of this finding has not been studied. We retrospectively studied 97 CLL patients with simultaneous information on sIFE and genetic alterations detected by next-generation sequencing.
View Article and Find Full Text PDFArticle Synopsis
- * A study involving 781 untreated stage A CLL patients compared five different risk scoring methods to see which best predicted disease progression, also assessing the impact of including the IGHV2 subset as a poor prognostic factor.
- * All five risk scores performed similarly in identifying low to high-risk patients, with CLL-IPI showing the best results, and findings indicate that incorporating IGHV2 could enhance the accuracy of these risk assessments.
Background: Current laboratory tests fail to evaluate the hemostatic function of platelets in patients with thrombocytopenia. We investigated the use of the Total Thrombus-Formation Analysis System (T-TAS 01 [Fujimori Kogyo Co, Tokyo, Japan]) to evaluate hemostasis under conditions of experimental thrombocytopenia, and in patients before and after platelet transfusion.
Materials And Methods: Specific T-TAS 01 chips, for thrombocytopenic conditions, were used.
Article Synopsis
- Watchful waiting is a viable management option for advanced-stage, low tumor burden patients with follicular lymphoma, but predicting how long this observation period will last is challenging.
- The study found that higher total metabolic tumor volume (TMTV) at diagnosis correlates with shorter observation periods, with patients having a TMTV above 50 mL experiencing significantly less time before requiring treatment.
- TMTV emerged as a strong predictor of time to first treatment, suggesting that once validated, it could help inform decisions about starting or delaying treatment for patients with low tumor burden follicular lymphoma.
Background: The major drug regulatory agencies have approved chimeric antigen receptor (CAR) T cells for the treatment of some B-cell lymphoproliferative diseases. Their use is expanding, and new indications will be approved. Efficient mononuclear cell collection by apheresis providing enough T cells is a critical step in further CAR T-cell manufacturing process.
View Article and Find Full Text PDFBackground And Objectives: Data about collection efficiency 1 (CE1), which takes into account blood cell counts before and after collection, thus providing a more accurate estimate, in the collection of autologous T lymphocytes by apheresis for chimeric antigen receptor (CAR) T-cells remain scarce. We evaluated donor- and procedure-related characteristics that might influence the CE1 of lymphocytes.
Materials And Methods: We retrospectively reviewed all mononuclear cell (MNC) collections) performed for CAR T-cell manufacturing in our institution from May 2017 to June 2021 in adult patients.
Article Synopsis
- Serum soluble CD23 (sCD23) levels in chronic lymphocytic leukemia (CLL) have been reaffirmed as a significant prognostic factor based on a study involving 338 patients.
- Patients with sCD23 levels over 1000 UI/L (41% of the cohort) exhibited worse clinical features and outcomes compared to those with lower levels.
- High sCD23 was linked to a quicker need for treatment and poorer overall survival rates, highlighting its potential role in predicting treatment responses in CLL.
The presence of a serum monoclonal component has been associated with poor outcomes in some lymphomas. However, data in follicular lymphoma (FL) are scarce. We studied 311 FL patients diagnosed at a single institution, for whom information on serum immunofixation electrophoresis (sIFE) at diagnosis was available.
View Article and Find Full Text PDF